The Annals the journal of Pharmacy Technology
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     

The Annals of Pharmacotherapy: Vol. 37, No. 3, pp. 327-331. DOI 10.1345/aph.1C125
© 2003 Harvey Whitney Books Company.
This Article
Right arrow Résumé Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Carroll, C. A
Right arrow Articles by Piepho, R. W
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Carroll, C. A
Right arrow Articles by Piepho, R. W

PHARMACOECONOMICS

Economic Impact of Ramipril on Hospitalization of High-Risk Cardiovascular Patients

Cathryn A Carroll, PhD MA MBA BSPharm

Assistant Professor, Division of Pharmacy Practice, University of Missouri, Kansas City, MO

Michael M Coen, MA MBA

Programmer/Biostatistician, Saint Luke's Health System, Mid America Heart Institute, Kansas City

Robert W Piepho, PhD

Dean and Professor, Division of Pharmacology, University of Missouri, Kansas City

Reprints: Cathryn A Carroll PhD MA MBA BSPharm, Division of Pharmacy Practice and Department of Economics, 107 Katz Hall, 5005 Rockhill Rd., Kansas City, MO 64110-2449, FAX 816/235-2834, E-mail carrollc{at}umkc.edu

OBJECTIVE: To estimate differences in direct costs attributable to avoided hospitalizations and procedures during the years of the HOPE (Heart Outcomes Prevention Evaluation) study after the cost of treatment with ramipril or alternative angiotensin-converting enzyme inhibitor therapy was taken into account.

METHODS: A decision analytical model was developed to estimate the economic impact of reductions in hospitalizations and/or procedures both at annual increments and over the first 4 years of the HOPE study. The analysis compared the number of cardiovascular events per endpoint per year in the intervention and placebo group with hospitalization and procedural costs. Cost data were derived from the literature and inflated to the appropriate index year using the consumer price index.

RESULTS: For approximately 9000 patients studied, the gross estimated savings in direct costs for 297 events avoided were more than $5 million over 4 years. After the cost of treatment was deducted for both groups, the net estimated savings were $871 000 over 4 years.

CONCLUSIONS: The results demonstrate that the use of ramipril provides cost-effective treatment for high-risk cardiovascular patients with an ejection fraction >40%.

Key Words: cardiovascular disease, cost, ramipril

Published Online, January 13, 2003. www.theannals.com, DOI 10.1345/aph.1C125


This article has been cited by other articles:


Home page
 CMAJHome page
S. Yusuf and G. Dagenais
More than just hype
Can. Med. Assoc. J., June 24, 2003; 168(13): 1646 - 1646.
[Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
D. W Raisch, S. S Netravali, and C. L Harris
Pharmacoeconomic Implications of Large Multicenter Clinical Trials
Ann. Pharmacother., March 1, 2003; 37(3): 447 - 450.
[Full Text] [PDF]


homecopy help contact us subscription past issues search current issue
Copyright © 2003 by Harvey Whitney Books Company.